Novo Nordisk A/S (NYSE:NVO) Stock Holdings Boosted by Dillon & Associates Inc.

Dillon & Associates Inc. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.4% during the 4th quarter, HoldingsChannel reports. The fund owned 287,476 shares of the company’s stock after buying an additional 4,059 shares during the period. Novo Nordisk A/S comprises 3.4% of Dillon & Associates Inc.’s portfolio, making the stock its 6th biggest holding. Dillon & Associates Inc.’s holdings in Novo Nordisk A/S were worth $24,723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Mosley Wealth Management grew its holdings in shares of Novo Nordisk A/S by 22.2% during the fourth quarter. Mosley Wealth Management now owns 4,912 shares of the company’s stock worth $413,000 after purchasing an additional 892 shares in the last quarter. Guardian Partners Inc. purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $10,910,000. Harbor Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $241,000. Fortis Capital Management LLC boosted its stake in Novo Nordisk A/S by 31.7% in the fourth quarter. Fortis Capital Management LLC now owns 45,888 shares of the company’s stock worth $3,947,000 after buying an additional 11,039 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC boosted its stake in Novo Nordisk A/S by 9.0% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 4,598 shares of the company’s stock worth $396,000 after buying an additional 380 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Price Performance

NVO opened at $76.88 on Monday. The stock has a fifty day simple moving average of $83.34 and a two-hundred day simple moving average of $100.74. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market cap of $344.98 billion, a price-to-earnings ratio of 23.37, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $73.80 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.